These actions produce its contraceptive effect. WHO (1991): age, center, and age at first live birth. In the study, when cumulative exposure to DMPA was calculated, the fracture rate in users who received fewer than 8 injections was higher than that in women who received 8 or more injections. Women who have or have had a history of breast cancer should not use hormonal contraceptives, including medroxyprogesterone acetate injectable suspension, because breast cancer may be hormonally sensitive Lee et al. This information does not take the place of talking with your gynecologist or other healthcare provider who specializes in women's health. Be alert to the possibility of an ectopic pregnancy among women using medroxyprogesterone acetate injectable suspension who become pregnant or complain of severe abdominal pain. Institute emergency medical treatment if an anaphylactic reaction occurs. When switching from other contraceptive methods, medroxyprogesterone acetate injectable suspension should be given in a manner that ensures continuous contraceptive coverage based upon the mechanism of action of both methods, (e.g., patients switching from oral contraceptives should have their first injection of medroxyprogesterone acetate injectable suspension on the day after the last active tablet or at the latest, on the day following the final inactive tablet). No adverse effects have been noted. (e) Coagulation test values for prothrombin (Factor II), and Factors VII, VIII, IX, and X may increase. (Medroxyprogesterone acetate injectable suspension is indicated only for the prevention of pregnancy. No trends in risk with duration of use or times since initial or most recent exposure were observed. [Medroxyprogesterone acetate injectable suspension, USP, a contraceptive injection, contains medroxyprogesterone acetate, USP a derivative of progesterone, as its active ingredient. Medroxyprogesterone acetate injectable suspension should not be administered during pregnancy. What is medroxyprogesterone acetate injectable suspension? Dosage does not need to be adjusted for body weight [To ensure the patient is not pregnant at the time of the first injection, the first injection should be given ONLY during the first 5 days of a normal menstrual period; ONLY within the first 5-days postpartum if not breast-feeding; and if exclusively breast-feeding, ONLY at the sixth postpartum week. From an initial average body weight of 136 lb, women who completed 1 year of therapy with medroxyprogesterone acetate injectable suspension gained an average of 5.4 lb. The box on the bottom of the chart shows the chance of getting pregnant for women who do not use birth control and are trying to get pregnant.Do not use medroxyprogesterone acetate injectable suspension if you: If you are breastfeeding or plan to breastfeed, medroxyprogesterone acetate can pass into your breast milk. In the two clinical trials with medroxyprogesterone acetate injectable suspension, over 3,900 women, who were treated for up to 7 years, reported the following adverse reactions, which may or may not be related to the use of medroxyprogesterone acetate injectable suspension. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Ses actions pharmacologiques sur le système endocrinien sont: … Mechanism Of Action Ceftin - Best pharmacy 2019. There have been reports of serious thrombotic events in women using medroxyprogesterone acetate injectable suspension (150 mg). Both increases and decreases in total cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol have been observed in studies. Patients should be counseled that medroxyprogesterone acetate injectable suspension does not protect against HIV infection (AIDS) and other sexually transmitted diseases. The following laboratory tests may be affected by progestins including medroxyprogesterone acetate injectable suspension: (a) Plasma and urinary steroid levels are decreased (e.g., progesterone, estradiol, pregnanediol, testosterone, cortisol).